Incyte (INCY) Stock Highlights

68.84 | +2.65%

2024-12-21 00:45:29

Incyte focuses on the discovery and development of small-molecule drugs. The firms lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incytes other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firms first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incytes pipeline includes a broad array of oncology and dermatology programs.

Statistics

Range Today

66.89 69.11

Volume Today 5.65M

Range 1 Year

50.35 83.95

Volume 1 Year 581.51M

Range 3 Year

50.27 86.29

Volume 3 Year 1.41B

Range 10 Year

50.27 153.15

Volume 10 Year 4.17B

Highlights

Market Capitalization 16.06B (large)

Floating Shares 160.21M

Current Price 68.84

Price To Earnings 917.56

Price To Revenue 3.46

Price To Book 5.07

Earnings Per Share 0.09

Payout Ratio 0%

Performance

Latest +2.65%

1 Month -2.58%

3 Months +3.99%

6 Months +12.36%

1 Year +11.03%

3 Years -6.63%

5 Years -25.18%

10 Years -9.54%

Benchmarks

Market Capitalization

10 / 368

Gross Profits

8 / 278

Total Revenue

5 / 300

Total Rank

9 / 368

Free Cashflow

4 / 352

Performance 5 years

141 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.